Inventor · disambiguated record
Julie Hambleton
Also filed as: HAMBLETON JULIE
11 granted patents·15 pending applications·49 citations·filing 2010–2025
88Inventor score
Top patents by PatentIndex Score
26 records- 0195US9765147B2Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2015·Granted Sep 19, 2017·25 cites·31 claims
- 0292US10221244B2Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2017·Granted Mar 5, 2019·10 cites·31 claims
- 0388US10618967B2Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2019·Granted Apr 14, 2020·5 cites·31 claims
- 0484US10172937B2Method of treatment of malignant solid tumors with afucosylated anti-FGFR2IIIb antibodiesFIVE PRIME THERAPEUTICS INC·Filed 2016·Granted Jan 8, 2019·5 cites·32 claims
- 0581US2023212299A1Anti-CSF1R Antibody and Anti-PD-1 Antibody Combination Therapy for CancerFIVE PRIME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0676US10730949B2Method of treating PVNS with anti-CSF1R antibodiesFIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Aug 4, 2020·1 cites·35 claims
- 0775US12465636B2Method of making afucosylated anti-FGFR2IIIB antibodiesFIVE PRIME THERAPEUTICS INC·Filed 2021·Granted Nov 11, 2025·0 cites·13 claims
- 0875US10040858B2Anti-CSF1R antibodies for treating PVNSFIVE PRIME THERAPEUTICS INC·Filed 2015·Granted Aug 7, 2018·2 cites·56 claims
- 0971US11566076B2Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancersFIVE PRIME THERAPEUTICS INC·Filed 2020·Granted Jan 31, 2023·0 cites·25 claims
- 1069US2025269016A1Afucosylated Anti-FGFR2IIIB AntibodiesFIVE PRIME THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1166US11235059B2Afucosylated anti-FGFR2IIIB antibodiesFIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Feb 1, 2022·0 cites·59 claims
- 1266US10975153B2Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2015·Granted Apr 13, 2021·1 cites·29 claims
- 1365US2023192870A1Combination Anti-CSF1R and Anti-PD-1 Antibody Combination Therapy for Pancreatic CancerFIVE PRIME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1463US2020148756A1Anti-angiogenesis therapy for the treatment of previously treated breast cancerGENENTECH INC·Filed 2019·Application pending·0 cites
- 1560US2021009700A1Anti-CSF1R Antibodies for Treating PVNSFIVE PRIME THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1659US11421034B2Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancerFIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Aug 23, 2022·0 cites·15 claims
- 1759US2015050273A1Afucosylated anti-fgfr2iiib antibodiesFIVE PRIME THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 1858US2022195027A1Anti-angiogenesis therapy for the treatment of previously treated breast cancerGENENTECH INC·Filed 2022·Application pending·0 cites
- 1957US2019185555A1Anti-angiogenesis therapy for the treatment of previously treated breast cancerGENENTECH INC·Filed 2017·Application pending·0 cites
- 2057US2021317219A1Methods of Treating Conditions with Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2152US2015071924A1Anti-Angiogenesis Therapy for the Treatment of Previously Treated Breast CancerGENENTECH INC·Filed 2014·Application pending·0 cites
- 2251US2022401440A1Dosing regimens for a protein kinase c inhibitorIDEAYA BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 2351US2024207257A1Combination therapy comprising a pkc inhibitor and a mek inhibitorIDEAYA BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2446US2016067307A1Methods of treating cancerFIVE PRIME THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 2543US2011047103A1Anti-angiogenesis therapy for the treatment of previously treated breast cancerGENENTECH INC·Filed 2010·Application pending·0 cites
- 2643US2018280470A1Methods of treating cancerFIVE PRIME THERAPEUTICS INC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Julie Hambleton files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →